Donafenib, a derivative of sorafenib, is a novel oral small-molecule presenting complex multiple tyrosine kinase inhibiting mechanisms of action by blocking vascular endothelial growth factor receptor (VEGFR), Raf kinases, and platelet-derived growth factor receptor (PDGFR), thus blocking both angiogenesis and tumor cell proliferation [80]. Here, KDR is linked to neoplasm.